Lupin Q4 FY21: The country’s leading pharmaceutical company Lupine’s profit in the fourth quarter of FY 2021 increased by 18 per cent year-on-year. During this time the company has a net profit of Rs 460 crore. The company says that its profit has increased due to increased sales in the domestic and international markets. Lupine had a net profit of Rs 390 crore in the same quarter of the previous financial year. However, there has been some decline in the company’s revenue during this period. During this time the company has also launched many new products.
Company’s revenue decreased
In the fourth quarter of FY 2021, Lupine’s revenue fell 1.6 per cent year-on-year to Rs 3,783 crore. The company’s revenue in the same quarter a year ago was Rs 3845.7 crore. On a quarterly basis, there has been a decline of 5.8 per cent in revenue. However, EBITDA grew by 4.3 per cent on an annual basis to Rs 765.7 crore. While EBITDA margin stood at 18.8 percent in the March quarter. It was 13.8 percent in the same quarter a year earlier.
Net debt Rs 662.60 crore
Profit after tax in the March quarter increased 4.4 per cent year-on-year to Rs 518.38 crore. Whereas the profit before tax of the company was Rs 496.36 crore in the same quarter a year ago. At the end of 31 March 2021, the net debt of the company has risen to Rs 662.60 crore, while the net debt equity stood at 0.05 as on 31 March 2021. The company has a total net profit of Rs 1,216 crore during the financial year 2020-21, while it had a net loss of Rs 269 crore during the last financial year.
Sales increased in domestic market
The company has launched 3 products in the US market in the fourth quarter. At the same time, in the US generic market, now the company has a total of 168 products. During this time the company has filed 9 ANDAs, while 6 ANDAs have received approval from the US FDA. Sales in North America fell by 5.3 percent on an annual basis, contributing 40 percent or 1,495.2 million of total sales. On a quarterly basis, however, there has been 3.7 per cent growth. The company’s sales in the Jharelu market have been 7.9 per cent on an annual basis.